Ichnos Glenmark Innovation and AbbVie Announce Exclusive Global Licensing Agreement for ISB 2001, a First-in-Class CD38×BCMA×CD3 Trispecific Antibody

Ichnos Glenmark Innovation Illinois New York

ISB 2001 is currently in Phase 1 clinical trial in patients with relapsed/refractory multiple myeloma (R/R MM)View original content:https://www.prnewswire.co.uk/news-releases/ichnos-glenmark-innovation-igi-and-abbvie-announce-exclusive-global-licensing-agreement-for-isb-2001-a-first-in-class-cd38ObcmaOcd3-trispecific-antibody-302502601.html